Mirvetuximab soravtansine-gynx ya amince da USFDA don FRα tabbatacce, platinum-resistant epithelial ovarian, tube fallopian, ko ciwon daji na peritoneal na farko.
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, platinum-resistant epithelial ..
Gwajin gwaji
MESO-CAR T Kwayoyin Farfadowa don Maimaitawa da Ciwon Ciwon Ciwon Kwai
March 2023: Brief Summary: The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has come back or stopped responding to other..
mirvetuximab soravtansine-gyn
Mirvetuximab soravtansine-gynx an ba da izinin haɓaka don FRα tabbatacce, platinum-resistant epithelial ovarian, tube fallopian, ko ciwon daji na peritoneal.
Nuwamba 2022: Ga manya marasa lafiya waɗanda suka sami tsarin tsarin magani ɗaya zuwa uku kafin su kuma suna da folate receptor alpha (FR) tabbatacce, platinum-resistant epithelial ovarian, tube fallopian, ko ciwon daji na peritoneal na farko, F..
Lancet, Mai bin izini, Tamoxifen, Trametinib
Sabuwar magani da aka gano don ƙarancin daraja da ciwon daji na kwai
Mayu 2022: Trametinib na iya zama sabon ma'auni na kulawa don maimaituwa, ƙananan ciwon daji na ovarian (Mekinist). Dangane da binciken binciken da aka buga a cikin Fabrairu 2022 fitowar The Lancet, trametinib ya doke duka biyun chemotherapy.
Cytalux, NCT03180307, pafolacinine, Dakunan gwaje-gwaje na Target
An amince da Pafolacianine don gano mummunan ciwon daji na ovarian
Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), wakili na hoto na gani, Hukumar Abinci da Magunguna ta sami lasisi don manya masu fama da ciwon daji na kwai a matsayin mai ba da taimako don gano tsaka-tsaki na ...
Niraparib
Niraparib ya sami sakamako mai ban mamaki ga ƙwarjin kwan mace da na mama
Nono & cancer na ovaries Idan kai mai haƙuri ne da cutar sankarar mahaifa, za ka ga cewa kai kansar ne na maye gurbin BRCA1 / 2 bayan ka wuce gwajin kwayar, kuma ranka ya tsira. A cewar Global Oncolog ..
Akalabrutunib, Avelumab, CART far, Dabrafanib, Kimiya, Sabbin magunguna, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Sabbin magunguna na maganin cutar kansa
Yuli 2021: Duba sabbin magunguna a cikin maganin cutar kansa. Kowace shekara, bayan nazarin gwaje-gwajen da wasu muhimman abubuwa, USFDA ta amince da kwayoyi, don haka masu ciwon daji za su iya gaskata cewa magani ya kusa. ..